NNRTI

abbr.

non-nucleoside reverse transcriptase inhibitor

American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

ThesaurusAntonymsRelated WordsSynonymsLegend:

Noun

NNRTI - an antiviral drug used against HIV; binds directly to reverse transcriptase and prevents RNA conversion to DNA; often used in combination with other drugs

non-nucleoside reverse transcriptase inhibitor

delavirdine, Rescriptor - a non-nucleoside reverse transcriptase inhibitor (trade name Rescriptor) used to treat AIDS and HIV

drug cocktail, HAART, highly active antiretroviral therapy - a combination of protease inhibitors taken with reverse transcriptase inhibitors; used in treating AIDS and HIV

nevirapine, Viramune - a non-nucleoside reverse transcriptase inhibitor (trade name Viramune) used to treat AIDS and HIV

reverse transcriptase inhibitor - an antiviral drug that inhibits the action of reverse transcriptase in retroviruses such as HIV

Translations

NNRTI

abbr non-nucleoside reverse transcriptase inhibitor. V. inhibitor.

Mentioned in

References in periodicals archive

Edurant (rilpivirine) is a once daily non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of human immunodeficiency virus (HIV-1) infection in combination with other antiretroviral agents in antiretroviral treatment-naive patients 12 years of age and older and weighing at least 35-kg with a viral load <= 100,000 HIV RNA copies/mL.

ViiV Healthcare Submits New Drug Application to US FDA for the First Monthly, Injectable, Two-Drug Regimen of Cabotegravir and Rilpivirine for Treatment of HIV

Olgularin %49.5'i INI, %8.2'si NNRTI ve %42.3'u PI temelli ART rejimi kullanmistir (Tablo 1).

Comparison of Antiretroviral Therapy Regimens With Regard to Virological and Immunological Response in Treatment-Naive HIV/AIDS Patients/Tedavi Naif HIV/AIDS Hastalarinda Kullanilan Antiretroviral Tedavi Rejimlerinin Virolojik ve Immunolojik Yanit Acisindan Karsilastirilmasi

Data on the use of boosted PIs together with an NNRTI are less promising.

Current Antiretroviral Therapies and Future Trends in Management of Human Immunodeficiency Virus-1 Infection

Of these, 2 had nucleoside reverse transcriptase inhibitor (NRTI) resistance, 2 had NNRTI resistance, 7 had both NNRTI and NRTI resistance and 2 had both PI and NRTI resistance.

Treatment outcomes in perinatally infected HIV-positive adolescents and young adults after >10 years on antiretroviral therapy

Olgularin 46'sina PI, 44'une INSTI ve besine NNRTI bazli kombinasyonlar baslandi.

Antiretroviral Tedavi Yan Etkilerinin Degerlendirilmesi/The Evaluation of the Side Effects of AntiretroviralTreatment

These include exposure to nevirapine or efavirenz for PMTCT, with expected universal selection of NNRTI mutations in the exposed, and even modest rates of RMs in the unexposed (a reported rate of 24% in a PMTCT-unexposed population in South Africa (SA)).

Lamivudine monotherapy in children and adolescents: The devil is in the detail

The observed numbers of RAMs against PI, NRTI and NNRTI are listed in Table 2.

Observed HIV drug resistance associated mutations amongst naive immunocompetent children in Yaounde, Cameroon

[9] The World Health Organization (WHO, 2010 revision) guidelines recommend initiation of antiretroviral therapy with two NRTI (zidovudine or tenofovir disoproxil fumarate with lamivudine [3TC] or emtricitabine [FTC) and a NNRTI (efavirenz [EFV] or nevirapine).

Comparison of the efficacy and safety of 2 different antiretroviral regimens in tertiary care hospital: A retrospective observational study

Depending on age, availability and as per WHO recommendations at the time of diagnosis, a combination of the two NRTIs (ZDV and 3TC) plus either NNRTI (nevaripine) or the PI (nelfinavir) was used to initiate therapy.

Lessons from a seven-year experience of paediatric HIV in Pakistan: A single centre experience

Predictor variables were sociodemographic characteristics (age at ART start, sex, marital status, city of residence, and occupation category); factors related to health care system utilization (referral center of attendance, mean number of medical visits per year, time between HIV diagnosis and ART initiation, and registration of hospitalization); clinical and laboratory data (T-CD4+ lymphocyte count and viral load at ART start and recording of AIDS-defining illness before first ART prescription); and first ART regimen, classified into two categories: combination of two nucleoside transcriptase inhibitors (NRTIs) and a nonnucleoside transcriptase inhibitor (NNRTI) and two NRTIs and a ritonavir- (RTV-) boosted or unboosted protease inhibitor (PI).

Incidence and Predictors of Antiretroviral Treatment Modification in HIV-infected Adults: A Brazilian Historical Cohort from 2001 to 2010